Advanced
  Home Compare Reports

Comparison with Similar Reports

Global Pharmaceutical and Biotechnology Outlook 2014 - Japan Pharma

Publisher:        MP Advisors

# of Pages:        141

Rating: 

1 User License $2,500

Publication Date:  January, 2014

Price:       $2,500 / User License




GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY
OUTLOOK 2014

JAPAN PHARMA

Table of contents

MACRO ANALYSIS: Price-cuts will bring pain to many in 2014! Innovators tremble while generics look witless!

INNOVATORS:
• New Price-Cuts – A Double Punch To The Innovators!
o Table 1- NEW SLABS FOR NHI PRICE CUTS FOR LONG-LISTED DRUGS
o Table 2 - EXPENSE VS. PROFITABILITY OF JAPANESE INNOVATORS
• Another Blow For Innovators In Not Institutionalizing The ‘Innovation Premium’

GENERICS:
• Pressure To Generic Discount Further Increased
• Upcoming New Generics
• Existing Generics
o Table 3 - NEW DRUG PRICES FOR EXISTING GE DRUGS
• Listing Of GE Drugs by Both GE Name And Brand To Promote Discounting

IMPLICATIONS:
o Finding New Avenues Of Cost Saving Are Inevitable For GE Cos
o Innovators Need To Redefine Long-Listed Products Strategies
o Consolidation Activities To Will Witness A Boost
o Table 4 -OTHER REGULATION UNDER APRIL-14 REFORMS*
o Table 5 -Profitably Structure Of Select Generic Companies


Annexure 1 JAPAN GENERICS MARKET MODEL

Annexure 2 JAPANESE INNOVATORS: LONG LISTED EXPOSURE

Annexure 3 PATENT EXPIRY THROUGH 2016


JAPAN INNOVATORS

ASTELLAS: Successful Global Launch of Xtandi And Myrbetriq To Overcome Domestic worries!

Prograf Generics Launch in Japan
Xtandi
• JP Approval ahead than Zytiga
• What to watch out for in Detailed PREVAIL data in Late Feb at ASCO GU-14?
• Prevail top line data of Xtandi – rPFS advantage and ease of use compensate absolute OS disappointment for urologist
• Recent US prescription trends of Xtandi are encouraging
Isavuconazole: Isavuconazole QIDP designation and our expectation
• Competitive landscape of Antifungals
Myrbetriq
• Early prescription trend
• Target market
• Competitive landscape for OAB drugs

Table 1: Deals done by Astellas in 2013
Table 2: Clinical data Comparison Xtandi vs. Zytiga
Table 3: Pipeline early stage Androgen receptor antagonist
Table 4: Competitive landscapes for Antifungals
Table 5: Competitive landscape for OAB drugs
Table 6: Key Milestones


Chugai: New Wave of Products Will Help Maintain Leadership Of Japan’s Biotech!!!

Long listed product exposure vs. Sales growth of newly launched products
Actemra in 2014
• Penetration of Actemra in first line setting
• Actemra Japan Uptake of SC formulation
• Actemra ongoing clinical trials
• Japan RA market
Chugai’s Breast Cancer Franchisee:
• Slower uptake expected than Global market for Perjeta in Japan, While for Kadcyla price listing in April is key for timely launch
• In long term, Perjeta and Kadcyla franchisee in Japan will reduce threat of Herceptin Biosimilar
• Further indication expansion of Perjeta in Global Market
• Japan dynamics would be different than global market for Perjeta
• Kadcyla vs. Tykerb in 2nd/3rd line breast cancer





Chugai’s NSCLC franchisee:
• Launch of “Made in Japan ALK inhibitor” from Chugai’s in house pipeline
• Tarceva indication expansion
MPDL3280A – Anti PD1 from Roche- status in Japan
2014 Price cut least impact amongst peers
• Tamiflu, Mircera, Boniva

Table 1: Actemra Ongoing Global trials
Table 2: Japan RA market
Table 3: Efficacy and Safety Comparision of Kadcyla vs. Trastuzumab + Docetaxel in FL BC
Table 4: Ongoing Clinical studies of Kadcyla in late stage HER2 positive Cancers
Table 5: Deals done by Chugai Pharma in 2013
Table 6: Key Milestones

Annexure 1: Possibility of Roche increasing its stake in Chugai is real and high
Annexure 2: Roche Chugai Maturing Relationship timeline
Annexure 3a: Potential benefits to Roche by increasing stake in Chugai
Annexure 3b: Chugai- Widening prospects of Actemra


Daiichi Sankyo: More Gain, Less Pain in 2014!

Vision 2017 is achievable
ENGAGE AF outcome did not disappoint, focus now shifts to launch and global partnering:
• Rx trends Suggest OD daily dosing matters in Oral anticoagulants:
• ENGAGE AF Data does not disappoint
• Japanese filing in VTE is encouraging
Chart 1: ORAL ANTICOAGULANTS: TRX TREND
Daiichi Sankyo Espha (DSE) – can unfold as a game changer in Japan generic market:
Table 1: PATENT EXPIRY THROUGH 2016
Table 2: DAIICHI SANKYO ESPHA APPROVALS UNTIL 2012
Table 3: DAIICHI SANKYO ESPHA APPROVALS IN 2013

Daiichi Sankyo Enjoys Greater Geographic Diversity And Revenue Sustainability Than Its Peers:
• High geographical diversity support in long run on multiple fronts:
Table 4: SALES – REGIONWISE
• KEY PRODUCTS REVENUE BASE RELATIVELY SUSTAINABLE COMPARED TO PEERS
Table 5: SALES TRAJECTORY IN JAPAN OF KEY PRODUCTS - THRU 2017
Table 6: EXPOSURE TO LONG LISTED PRODUCTS

Annexure 1: 5-YEAR BUSINESS PLAN: NUMERICAL TARGETS FOR FY2017
Annexure 2: CORE STRATEGIES OF 5-YEAR BUSINESS PLAN
Annexure-3: NEW GENERATION ORAL ANTICOAGULANTS – MARKET DYNAMICS





Dainippon Sumitomo Pharma – Expectation from BBI-608 to Achieve FY2017 MTP Target looks Unachievable

Summary of the company’s ongoing activities and strategy

BBI-608 Optimism is too high
• Lead indication mCRC opportunity limited- Efficacy advantage in PhII study with standard of care needs to justify dual agent cost
• Pipeline Cancer Stem Cell inhibitors
• Conceptually targeting cancer stem cell approach is revolutionary, but it is still not validated in the clinic
o Failure of Imetelstat raises some questions on the approach
o Probable MOA of BBI-608 specific or not in mCRC
• A success fee partnering model demands high peak sales to translate meaningfully on bottom lines for DSP

Latuda- US blockbuster potential likely while opportunities in bipolar maintenance and IM depo formulation are limited
• Latuda prescription trend post bipolar disorder approval
• Latuda EU/JP approval

STEDESA/Aptiom US approval and uptake

Other Pipeline candidates
• DS-3025
• AS-3201
• SMP-986

Chart 1: Presence of stem cell in colon tissue
Table 1: Markers to identify colon stem cells and colon cancer stem cells
Table 2: Competitive landscape Metastatic colorectal cancer
Table 3: Early stage data Comparision of Cancer stem cell inhibitors targeting colon cancer
Table 4: Pipeline of drugs targeting cancer stem cell
Table 5: Pipeline of Boston Biomedical
Table 6: Psychiatrists see high unmet need
Chart 2: Atypical antipsychotics market
Table 7: PEARL 3 clinical study data of Latuda vs. Seroquel
Table 8: Latuda SWOT analysis
Table 9: Latuda extension study data
Table 10: Dianippon Sumitomo- Key pipeline candidates and expected filing
Table 11: Deals done by Dainippon in 2013 and our view
Table 12: Key events expected in next two years and our expectation on it


Eisai- Multiple Challenges, Little Hope!
Eisai Key Thesis
Table 1: KEY PIPELINE CANDIDATES
Table 2: DEPENDENCE ON LONG LISTED DOMESTIC PRODUCTS
Halaven - Promising In Triple Negative Breast Cancer, Many New Indications Underway And May Succeed:
Table 3: HALAVEN –INDICATIONS UNDERWAY
Table 4: HALAVEN : UPCOMING COMPETITION
Fycompa approved in US as adjuvant therapy for refractory partial seizure, but potential will be limited due to genericization of the market
Table 5: FYCOMPA CLINICAL DATA
Table 6: DATA PRESENTED AT IEC ANNUAL MEETING 2011
High Expectations from Belviq are not justifiable - Label Restrictions Will confine Peak-Sales from reaching $500m. Agreement terms with Arena leave little for Eisai on bottom line:
Featured Late Stage Pipeline – High Risk Candidates Await More Clarity On Data
Levantine Progressing Well
Table 7: LEVANTINE – WIDE INDICATION RANGE
Farletuzumab has lost attractiveness
E-5501 Looks Interesting So Far, Data Awaited for a Long
Chart 1: E-5501 - SHORT AND LONG TERM PLATELET RESPONSES
Eritoran (E5564) Looks Dormant in Pipeline


Kyorin- Time to display its Respiratory Strength in Japan

Kyorin Key summary
• Teijin group acquires a stake in Kyorin- What next???
KRP-AB1102/KRP-AB1102F
• JP status
• US sales trend
• Our view
KRP-108
• Our view on its expected uptake in Japan
• Its uptake in EU is very slow- but why it will not be the same case for Japan
• Asthma market dynamics in Japan
• Kyorin- Skyepharma agreement on KRP-108
Kipres & Uritos: Growing steadily but will face competition
Mucodyne sales trend and Pentasa line extension
Other pipeline candidates in early stage development
• KRP-203
• KRP-209
• KRP-EPA605
• KRP-AM1977X and KRP-AM1977Y
Chart 1: US prescription tend of recently launched drugs in respiratory therapy class
Chart 2: Flutiform vs. Seretide (Advair) - Head to head efficacy comparison
Table 1: Flutiform competition in Japan
Table 2: Flutiform: Key pipeline candidates in JP asthma market
Table 3: Key events expected in next two years and our expectation on it


Kyowa hakko Kirin – A long way to go to become a Global Speciality Pharma

Kyowa Hakko Kirin - Key summary
• KHK’s Potelligent technology
• Biosimilar JV
Our view on its global late stage pipeline candidates
• KW-0761
• KW-6002
• KRN-23
• MEDI-563/Benralizumab/KHK4563
Newly launched products in domestic market
• Poteligeo- First Potelligent based antibody in market
• KW-6002
• Onglyza

Table 1: KHK: Global Pipeline – expected launch, peak sales estimates and upcoming milestones
Table 2: Parkinson’s disease competitive landscape of recently launched PD Drugs in Japan
Table 3: Deals done by KHK in 2013
Table 4: KHK- Potelligent technology
Table 5: Key events expected in next three years and our expectation on it

Mitsubishi Tanabe – Near term growth dependent on the competiton faced by Gilenya and Invokana

Mitsubishi Tanabe - Key summary
• Growth drivers vs. long listed exposure
• Our view on MT’s acquisition strategy
Invokana- US prescription trend is encouraging but warrant a caution
• Invokana US prescription vs. newly launched products in type 2 diabetes space
• Invokana cost vs. Victoza cost
• EU uptake of Forxiga
• Japan market dynamics for SGLT2 inhibitors
• Our expectation on market share for Invokana vs. Empagliflozin vs. dapagliflozin
• What to watch in SGLT2 class globally next??- LX4211, Empagliflozin ….
Tenelia prospects post Invokana launch
Gilenya: 2013 A year of Gilenya: BG-12 US launch has not impacted yet what next…
• Our view on Gilenya growth going forward & upcoming competition
• Key reasons why Gilenya will continue to Maintain its market share in the new competitive landscape
Remicade Growth in Japan - Biosimilar Remicade entry in Japan and our view on its impact
• Simponi
• Simponi ARIA
STENDRA (Avanafil) would not add much
Telavic growth is dampen in Japan
MT-4666
MT’s early stage global pipeline – Peak sales estimates, our view and upcoming milestones
• MT-3995, MT-9938, MP-157, MP-124, T-0047/SB-683699, MN-305
• MT-1303, MT-210, STU-199, TT-138, Wf-516


Chart 1: US prescription trend of Invokana
Chart 2: US prescription trend of Invokana vs. Victoza
Table 1: Five post marketing studies required by FDA on Invokana
Table 2: SGLT2 inhibitors- Efficacy Comparision
Table 3: SGLT2 inhibitors - Safety Comparision
Table 4: SGLT2 pipeline - Japan and Global status
Table 5: Marketed DPP-IV inhibitors in Japan, FY12 sales and Patent expiry
Table 6: Multiple Sclerosis: Oral drugs data Comparision
Table 7: Co-Pay difference to patients if biosimilar replace original Mab in Japan
Table 8: Clinical data Comparision of CT-P13 (Remicade biosimilar) vs. Remicade in RA
Table 9: Pipeline Remicade biosimilar in Japan
Table 10: Available biosimilar in Japan
Table 11: Avanafil Relative positioning
Table 12: MT- Pipeline analysis of early stage global candidates
Table 13: Deals done by MT in 2013
Table 14: Key events expected in 2014 and our expectation on it


Shionogi – Tivicay uptake is the key until next batch of Innovation

Shionogi- Key summary
Tivicay-
• US early prescription trend
• Market dynamics one all three integrase inhibitors on market
• Approval of Trii-FDC combination
• Tivicay- a huge potential beyond integrase inhibitor space
• What next to look for in the integrase inhibitor space?
Crestor: NRx/TRx show better resilience / Impact of IMPROVE- IT study
Low margin Domestic business not going to change soon
Pipeline has potential but unlikely to give breakthroughs in near term
US business: Nothing left for further downside

Chart 1: Tivicay Early prescription trend
Chart 2: Current HIV treatment Paradigm
Table 1: Competitive landscape – Integrase inhibitors
Table 2: Dolutegravir PhIII trials
Table 3: Tivicay- SINGLE Trial data
Table 4: SPRING-2 Trial data
Table 5: Deals done by Shionogi in 2013
Table 6: Key events expected in 2014 and our expectation on it



Takeda – Challenges Ahead for its New European President

Takeda - Key summary
EU New products launch in near term get modest help from Nycomed presence while in long term expected launch of vedolizumab and Natura alpha in IBD market will get big boost

Vortioxetine- US launch for MDD likely in Early 2014, Competitive enough against genericized MDD market
• Edivoxetine failure a moderate positive
• Brexpriprazole clinical development needs a close watch
• Vortioxetine vs. currently available drugs
• Pipeline drugs ready to unfold in 2014 in major depressive disorder market

Vedolizumab approval and our expectation
• Vedolizumab different mechanism of action
• Vedolizumab does not carry the risk of developing PML as Tysabri although follows the same pathway
• Efficacy comparable to currently available second line options
• Safety data looks impressive vs. currently approved drugs
• Competition from pipeline drugs
• Upcoming near term milestones in UC/CD indication

MLN-9708/Velcade- Our view on Takeda’s multiple myeloma franchise
• MLN-9708 in NDMM and RRMM
• Competitive landscape
• PhIII trial design
• Update post EHA and ASCO 2013
• Current treatment options NDMM and RRMM
• Velcade post launch of Kyprolis and Pomalyst
• Expected competition to Velcade in second/third line setting and upcoming milestones before patent expiry (2017)
• Recent approvals of Kyprolis and Pomalyst in RRMM have set a new bar for efficacy

TAK-700 – Unable to demonstrate OS benefit in chemo experienced patients- What to expect in chemo naïve pool and in earlier setting???
• Xtandi – the real bar in earlier setting
• Key Milestones to watch out for TAK-700 in 2014
• TAK-700 vs. Zytiga

Our view on Takeda’s other important growth drivers in 2014
• SYR-322 - Japan and US sales trend
• EDARBI- Outlicensing deal with Arbor pharma – a smart move
• Adcetris


Table 1: Deals done by Takeda in 2013
Table 2: Key late stage pipeline candidates- Expected launch and peak sales estimate
Table 3: Vortioxetine- Major depressive disorder- late stage pipeline
Chart 1: Anti-depressants – WW Competitive landscape
Table 4: Vortioxetine- Major depressive disorder- Early stage pipeline
Table 5: Vortioxetine- MDD – Drugs discontinued in the recent past
Table 6: Vortioxetine- Major Depressive disorder- Competitive landscape
Table 7: Vedolizumab- Pipeline leukocyte Traffic inhibitor (Integrin inhibitor)
Table 8: Vedolizumab vs. Marketed Mab in Ulcerative colitis
Table 9: Vedolizumab vs. Marketed MAB in Crohn’s disease
Table 10: Vedolizumab Clinical trial Programme
Chart 2: MLN-9708 Trial design
Chart 3: Reported adverse events in clinical trials- MLN9708
Table 11: MLN 9708- Data Comparision- Newly diagnosed Multiple Myeloma
Table 12: MLN 9708- Data Comparision- Relapsed and refractory Multiple Myeloma
Table 13: TAK-700 Comparision of CY17 inhibitors pipeline drugs action on Androgen synthesis
Chart 4: TAK-700- Drugs acting through androgen pathway in Prostate cancer
Table 14: Key candidates of Antiandrogen therapy in Prostate Cancer
Chart 5: Nesina US prescription trend
Table 15: Key events expected in next year and our expectation on it

JAPAN GENERICS

Nippon Chemiphar - Overseas Expansion – An attempt to improve thin margins, Wavering Profitability outlook

Nippon Chemiphar- Different from pure play generic player

Impact of April 14 NHI price revision
Table 1: Nippon Chemiphar: Generic Sales Break up

Lowest profitability structure in not going to change soon
Table 2: Generic companies with NCE research focus- FY 2013 sales estimate and growth rate


Sawai - Growth Story Continues!

A Balanced Therapy Focus, Warrants Sustainable Base
Table 1: BALANCED THERAPY FOCUS
Wider Distribution Base to Exploit All Markets
Table 2: BALANCED DISTRIBUTION FOCUS
Constantly growing manpower base
Table 3: CONSTANTLY GROWING MANPOWER BASE
Japan Generic Macro Thesis
• Likely Consolidation Activities
• NHI Price Cuts and GE Friendly Reforms in April-14
• Changing Market Dynamics With the Debut of Foreign Players in Japan GE Space
• Price War’ Does not Work Well in Japan
• Market Opportunity is Large Enough to ‘Feed’ Everyone

Table 4: FOREIGN COMPANIES ENTRY IN JAPAN GENERIC MARKET
Table 5: SAWAI VS. KEY COMPETITORS SALES BREAK UP
Chart 1: JAPAN GENERIC MARKET: POTENTIAL VS. PENETRATION


Towa - 2014 – Testing Year for ‘Premium Pricing’ Strategy!
Direct sales model likely to maintain high margin business
Recent Investments Will Start Yielding Returns Soon
Conventional Business Model is Sustainable
Likely Consolidation Activities
NHI Price Cuts and GE Friendly Reforms in April-14
Table 1: DISTRIBUTION TREND
Chart 1: CAPEX TO MEET FUTURE DEMAND
Table 2: TOWA VS. KEY COMPETITORS SALES BREAK UP
Table 3: FOREIGN COMPANIES ENTRY IN JAPAN GENERIC MARKET
Chart 2: Japan Generic Market: Potential vs. Penetration


Japan Pharma Industry Tables

Annexure 4: Key late stage pipeline/Newly launched drugs potential through 2018

Annexure 5: Therapy Area wise Deals done by Japan Innovators in 2013 161-166

Annexure 6: Expected Drug Clinical Milestones

Pharmaceutical Packaging Equipment Market by Product (Aseptic Packaging, Blister, Strip, Bottle, Tube, Carton, Case Packer, Wrapping Machine, Palletiz...

Publisher:        MarketsandMarkets

# of Pages:        378

Rating: 

1 User License $4,950

Publication Date:  March, 2022

Price:       $4,950 / User License




1 INTRODUCTION 39
1.1 OBJECTIVES OF THE STUDY 39
1.2 MARKET DEFINITION 40
1.2.1 INCLUSIONS AND EXCLUSIONS 40
1.3 MARKET SCOPE 41
1.3.1 MARKETS COVERED 41
FIGURE 1 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET SEGMENTATION 41
1.3.2 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: BY REGION 42
1.4 YEARS CONSIDERED FOR THE STUDY 42
1.5 CURRENCY 43
TABLE 1 STANDARD CURRENCY CONVERSION RATES 43
1.6 LIMITATIONS 43
1.7 STAKEHOLDERS 43
1.8 SUMMARY OF CHANGES 44
2 RESEARCH METHODOLOGY 45
2.1 RESEARCH DATA 45
FIGURE 2 RESEARCH DESIGN 45
2.1.1 SECONDARY DATA 46
2.1.1.1 Key data from secondary sources 47
2.1.2 PRIMARY DATA 48
FIGURE 3 PRIMARY SOURCES 48
2.1.2.1 Key data from primary sources 49
2.1.2.2 Key industry insights 50
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS 50
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 51
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 51
2.2 MARKET SIZE ESTIMATION 52
FIGURE 7 SUPPLY SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 52
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: SYNTEGON TECHNOLOGY GMBH 53
FIGURE 9 SUPPLY SIDE MARKET SIZE ESTIMATION: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET (2020) 54
FIGURE 10 APPROACH 3: BASED ON SOURCE, BY REGION (2022) 55
FIGURE 11 TOP-DOWN APPROACH 55
FIGURE 12 CAGR PROJECTIONS FROM DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES ANALYSIS (2022–2027) 57
FIGURE 13 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS 57
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 58
FIGURE 14 DATA TRIANGULATION METHODOLOGY 59
2.4 MARKET SHARE ESTIMATION 60
2.5 ASSUMPTIONS FOR THE STUDY 60
2.6 LIMITATIONS 60
2.6.1 METHODOLOGY-RELATED LIMITATIONS 61
2.7 RISK ASSESSMENT 61
TABLE 2 RISK ASSESSMENT: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 61
2.8 ASSESSMENT OF COVID-19 IMPACT ON ECONOMIC SCENARIO 61
3 EXECUTIVE SUMMARY 63
FIGURE 15 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT,
2022 VS. 2027 (USD MILLION) 63
FIGURE 16 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 64
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 65
4 PREMIUM INSIGHTS 66
4.1 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET OVERVIEW 66
FIGURE 18 RISING NEED FOR FLEXIBLE AND INTEGRATED PACKAGING EQUIPMENT TO DRIVE MARKET GROWTH 66
4.2 ASIA PACIFIC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT AND COUNTRY (2021) 67
FIGURE 19 PRIMARY PACKAGING EQUIPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF APAC MARKET IN 2021 67
4.3 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 68
FIGURE 20 CHINA TO REGISTER THE HIGHEST GROWTH DURING FORECAST PERIOD 68
4.4 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, REGIONAL MIX, 2022−2027 68
FIGURE 21 EUROPE TO DOMINATE PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 68
4.5 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: DEVELOPING VS. DEVELOPED MARKETS 69
FIGURE 22 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING
FORECAST PERIOD 69
5 MARKET OVERVIEW 70
5.1 INTRODUCTION 70
5.2 MARKET DYNAMICS 70
FIGURE 23 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 70
5.2.1 DRIVERS 71
5.2.1.1 High growth in generics & biopharmaceuticals markets 71
FIGURE 24 SALES OF GENERIC DRUGS GLOBALLY, 2006–2020 (USD BILLION) 71
FIGURE 25 GLOBAL PHARMACEUTICALS MARKET (USD BILLION) 71
TABLE 3 LIST OF OFF-PATENT DRUGS, 2015−2029 72
5.2.1.2 Growing need for flexible and integrated packaging equipment 73
5.2.1.3 Increase in offshore pharmaceutical manufacturing 73
FIGURE 26 PHARMACEUTICAL IMPORTS AND EXPORTS, BY COUNTRY,
2020 (USD BILLION) 74
5.2.1.4 Growing contract manufacturing of pharmaceutical products 74
5.2.1.5 Introduction of regulatory standards on packaging and stringent norms against counterfeit products 74
TABLE 4 KEY REGULATIONS & STANDARDS GOVERNING PHARMACEUTICAL PACKAGING EQUIPMENT 75
5.2.1.6 Innovation in pharmaceutical packaging and delivery system 75
5.2.1.7 Growth in OTC drug sales and regulations to reduce OTC counterfeit 76
FIGURE 27 GLOBAL OTC PHARMACEUTICALS MARKET SIZE, 2020 (USD BILLION) 76
5.2.2 RESTRAINTS 76
5.2.2.1 Growing preference for refurbished equipment 76
5.2.3 OPPORTUNITIES 77
5.2.3.1 Growth of pharmaceutical manufacturing in emerging economies 77
5.2.3.2 Rising demand for automated packaging 77
5.2.3.3 Change in medication systems to self-medication and self-care 78
5.2.3.4 Increasing pharmaceutical R&D investments 78
FIGURE 28 PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE,
2017–2024 79
FIGURE 29 NUMBER OF REGISTERED STUDIES, 2001-2022
(AS OF FEBRUARY 22, 2022) 79
FIGURE 30 NUMBER OF PIPELINE DRUGS, BY COMPANY, 2019 80
5.2.4 CHALLENGES 80
5.2.4.1 Growth in personalized and precision medicine supply chain 80
5.2.4.2 Uncertainties in regulations and standards of pharmaceutical packaging process 81
5.3 TECHNOLOGICAL ROADMAP 82
FIGURE 31 PHARMACEUTICAL PACKAGING EQUIPMENT: TECHNOLOGICAL ROADMAP 82
5.4 INDUSTRY TRENDS 83
FIGURE 32 MAJOR TRENDS IN PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 83
5.4.1 DEVELOPMENT OF PRODUCTION LINES FOR SMALL BATCH SIZES AND RESEARCH PURPOSES 83
5.4.2 AUTOMATION AND INTEGRATION OF PACKAGING EQUIPMENT 84
5.4.3 GROWING FOCUS ON LABELING AND SERIALIZATION FOR ANTI-COUNTERFEITING OF DRUGS 85
5.4.4 GROWING DEMAND FOR ASEPTIC FILLING AND SEALING EQUIPMENT 85
5.5 PRICING ANALYSIS 86
TABLE 5 AVERAGE SELLING PRICE (USD): PRIMARY PACKAGING EQUIPMENT 86
TABLE 6 AVERAGE SELLING PRICE (USD): SECONDARY PACKAGING EQUIPMENT 87
TABLE 7 AVERAGE SELLING PRICE (USD): LABELING AND SERIALIZATION EQUIPMENT 87
5.6 SUPPLY CHAIN ANALYSIS 87
FIGURE 33 SUPPLY CHAIN ANALYSIS 88
5.7 VALUE CHAIN ANALYSIS 88
FIGURE 34 VALUE CHAIN OF PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 89
5.8 ECOSYSTEM MARKET MAP 89
FIGURE 35 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET:
ECOSYSTEM MARKET MAP 89
5.9 PORTER’S FIVE FORCES ANALYSIS 90
TABLE 8 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: PORTER’S FIVE FORCES ANALYSIS 90
5.10 REGULATORY ANALYSIS 92
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 92
TABLE 11 ASIA-PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 93
TABLE 12 REST OF WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
5.10.2 NORTH AMERICA 94
5.10.2.1 US 94
5.10.2.2 CANADA 94
5.10.3 EUROPE 95
5.10.4 ASIA PACIFIC 95
5.10.4.1 Japan 95
5.10.4.2 China 95
5.10.4.3 India 95
5.10.5 BRAZIL 96
FIGURE 36 BRAZIL: REGULATORY PROCESS FOR PHARMACEUTICAL PACKAGING EQUIPMENT 96
5.11 KEY CONFERENCES & EVENTS IN 2022-2023 97
TABLE 13 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: DETAILED LIST OF CONFERENCES & EVENTS 97
5.12 YC–YCC TRENDS/DISRUPTION IMPACTING CUSTOMER BUSINESS 98
FIGURE 37 YC–YCC SHIFT IN PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 98
5.13 PATENT ANALYSIS 98
5.13.1 PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL PACKAGING EQUIPMENT 98
FIGURE 38 GLOBAL PATENT PUBLICATION TRENDS IN PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, 2015–2021 99
5.13.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 99
FIGURE 39 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR PHARMACEUTICAL PACKAGING EQUIPMENT PATENTS,
2015–2021 99
5.14 TRADE ANALYSIS 100
TABLE 14 PHARMACEUTICAL PACKAGING EQUIPMENT EXPORT AND IMPORT DATA,
BY COUNTRY 100
5.15 CASE STUDY ANALYSIS 101
FIGURE 40 CASE STUDY: SECURITY PACKAGING UPGRADES FOR PHARMACEUTICAL 101
5.15.1 CASE STUDY: QUALITATIVE INSIGHT BASED ON SPEED OF THE MACHINE 102
5.15.1.1 Sachet packaging equipment: 102
5.15.1.2 Blister packaging equipment: 102
5.15.1.3 Cartoning equipment: 104
5.16 IMPACT OF COVID-19 ON PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 107
6 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT 109
6.1 INTRODUCTION 110
TABLE 15 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 110
6.2 PRIMARY PACKAGING EQUIPMENT 110
TABLE 16 PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 111
TABLE 17 PRIMARY PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 112
6.2.1 ASEPTIC FILLING AND SEALING EQUIPMENT 112
6.2.1.1 Technological advancements and automation to drive segment growth 112
TABLE 18 EXAMPLES OF ASEPTIC FILLING AND SEALING EQUIPMENT 113
TABLE 19 ASEPTIC FILLING AND SEALING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 116
6.2.2 BOTTLE FILLING AND CAPPING EQUIPMENT 116
6.2.2.1 Higher adoption of plastic bottles in pharmaceutical packaging to support segment growth 116
TABLE 20 EXAMPLES OF BOTTLE FILLING AND CAPPING EQUIPMENT 117
TABLE 21 BOTTLE FILLING AND CAPPING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 118
6.2.3 BLISTER PACKAGING EQUIPMENT 118
6.2.3.1 Adaptability of blister packs to impact blister packaging equipment demand 118
TABLE 22 EXAMPLES OF BLISTER PACKAGING EQUIPMENT 119
TABLE 23 BLISTER PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 121
6.2.4 SOFT-TUBE FILLING AND SEALING EQUIPMENT 122
6.2.4.1 Increasing demand for soft-tube-based drug formulations and OTC pain relief ointments and creams to aid market growth 122
TABLE 24 EXAMPLES OF SOFT-TUBE FILLING AND SEALING EQUIPMENT 122
TABLE 25 SOFT-TUBE FILLING AND SEALING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
6.2.5 SACHET PACKAGING EQUIPMENT 124
6.2.5.1 Increasing applications of sachets and pouches in unit dose packaging to drive segment growth 124
TABLE 26 EXAMPLES OF SACHET PACKAGING EQUIPMENT 124
TABLE 27 SACHET PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 125
6.2.6 STRIP PACKAGING EQUIPMENT 125
6.2.6.1 User-friendly packaging of strips to drive segment growth 125
TABLE 28 EXAMPLES OF STRIP PACKAGING EQUIPMENT 126
TABLE 29 STRIP PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 127
6.2.7 COUNTING EQUIPMENT 127
6.2.7.1 Initiatives to develop remote tablet counting machines to improve accuracy and efficiency in medical dispensing 127
TABLE 30 EXAMPLES OF COUNTING EQUIPMENT 128
TABLE 31 COUNTING EQUIPMENT MARKET, BY COUNTRY, 2020–2027(USD MILLION) 129
6.2.8 OTHER PRIMARY PACKAGING EQUIPMENT 129
TABLE 32 OTHER PRIMARY PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027(USD MILLION) 130
6.3 SECONDARY PACKAGING EQUIPMENT 130
TABLE 33 SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 131
TABLE 34 SECONDARY PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 132
6.3.1 CARTONING EQUIPMENT 132
6.3.1.1 Safe and gentle packaging achieved with cartoning equipment usage to drive segment growth 132
TABLE 35 EXAMPLES OF CARTONING EQUIPMENT 133
TABLE 36 CARTONING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 135
6.3.2 CASE PACKING EQUIPMENT 135
6.3.2.1 Increasing demand for flexible packaging to support market growth 135
TABLE 37 EXAMPLES OF CASE PACKING EQUIPMENT 136
TABLE 38 CASE PACKING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 137
6.3.3 WRAPPING EQUIPMENT 137
6.3.3.1 Wrapping machines offer customization to increase productivity 137
TABLE 39 EXAMPLES OF WRAPPING EQUIPMENT 138
TABLE 40 WRAPPING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 139
6.3.4 TRAY PACKING EQUIPMENT 139
6.3.4.1 Technological advances to support segment growth 139
TABLE 41 EXAMPLES OF TRAY PACKING EQUIPMENT 140
TABLE 42 TRAY PACKING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 140
6.3.5 PALLETIZING AND DEPALLETIZING EQUIPMENT 141
6.3.5.1 Recent developments and automation in palletizing and depalletizing equipment to drive market growth 141
TABLE 43 EXAMPLES OF PALLETIZING AND DEPALLETIZING EQUIPMENT 141
TABLE 44 PALLETIZING AND DEPALLETIZING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 142
6.4 LABELING AND SERIALIZATION EQUIPMENT 142
TABLE 45 LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 143
TABLE 46 LABELING AND SERIALIZATION EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 144
6.4.1 BOTTLE AND AMPOULE LABELING AND SERIALIZATION EQUIPMENT 144
6.4.1.1 Increasing awareness about anti-counterfeit technologies to drive market growth 144
TABLE 47 EXAMPLES OF BOTTLE AND AMPOULE LABELING AND SERIALIZATION EQUIPMENT 145
TABLE 48 BOTTLE AND AMPOULE LABELING AND SERIALIZATION EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 146
6.4.2 CARTON LABELING AND SERIALIZATION EQUIPMENT 146
6.4.2.1 Increasing demand for pharmaceutical products labeling and serialization to drive market growth 146
TABLE 49 EXAMPLES OF CARTON LABELING AND SERIALIZATION EQUIPMENT 147
TABLE 50 CARTON LABELING AND SERIALIZATION EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 147
6.4.3 DATA MATRIX LABELING AND SERIALIZATION EQUIPMENT 148
6.4.3.1 Speed and ease of use to propel segment growth 148
TABLE 51 EXAMPLES OF DATA MATRIX LABELING AND SERIALIZATION EQUIPMENT 148
TABLE 52 DATA MATRIX LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 149
7 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE 150
7.1 INTRODUCTION 151
TABLE 53 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 151
7.2 LIQUID PACKAGING EQUIPMENT 151
TABLE 54 LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 152
TABLE 55 LIQUID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 152
7.2.1 ASEPTIC LIQUIDS 153
7.2.1.1 Automation of packaging lines and increasing use of robotics to propel aseptic liquid packaging 153
TABLE 56 EXAMPLES OF ASEPTIC LIQUID PACKAGING EQUIPMENT 154
TABLE 57 ASEPTIC LIQUID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 157
7.2.2 SYRUPS 158
7.2.2.1 Bottle filling and capping machines to reduce syrup spillage risk 158
TABLE 58 EXAMPLES OF SYRUP PACKAGING EQUIPMENT 158
TABLE 59 SYRUP PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 159
7.2.3 EYE/EAR DROPS 159
7.2.3.1 Technological advancements to increase demand for automated form-fill-seal equipment used for eye/ear drops packaging 159
TABLE 60 EXAMPLES OF EYE/EAR DROP PACKAGING EQUIPMENT 160
TABLE 61 EYE/EAR DROP PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 160
7.2.4 AEROSOLS 161
7.2.4.1 Integration of filling and sealing processes to gain importance in aerosol packaging 161
TABLE 62 EXAMPLES OF AEROSOL PACKAGING EQUIPMENT 161
TABLE 63 AEROSOL PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 162
7.2.5 OTHER LIQUID PACKAGING EQUIPMENT 162
TABLE 64 OTHER LIQUID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 163
7.3 SOLID PACKAGING EQUIPMENT 163
TABLE 65 SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 164
TABLE 66 SOLID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 164
7.3.1 TABLETS 165
7.3.1.1 Growing demand for packaging equipment capable of handling smaller batch sizes with higher levels of accuracy and precision to drive segment growth 165
TABLE 67 EXAMPLES OF TABLET PACKAGING EQUIPMENT 165
TABLE 68 TABLET PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 168
7.3.2 CAPSULES 168
7.3.2.1 Capsule-counting machines to integrate with filling and inspection systems 168
TABLE 69 EXAMPLES OF CAPSULE PACKAGING EQUIPMENT 169
TABLE 70 CAPSULE PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 170
7.3.3 POWDERS 170
7.3.3.1 High demand for robotic packaging equipment for powder packaging to proper segment growth 170
TABLE 71 EXAMPLES OF POWDER PACKAGING EQUIPMENT 171
TABLE 72 POWDER PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 172
7.3.4 GRANULES 172
7.3.4.1 Sachets to become most preferred packaging forms for granules 172
TABLE 73 EXAMPLES OF GRANULE PACKAGING EQUIPMENT 173
TABLE 74 GRANULE PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 173
7.3.5 OTHER SOLID PACKAGING EQUIPMENT 174
TABLE 75 OTHER SOLID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 174
7.4 SEMI-SOLID PACKAGING EQUIPMENT 175
TABLE 76 SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 175
TABLE 77 SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 176
7.4.1 OINTMENTS 176
7.4.1.1 Wide usage to drive pharmaceutical packaging equipment demand 176
TABLE 78 EXAMPLES OF OINTMENT PACKAGING EQUIPMENT 177
TABLE 79 OINTMENT PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 178
7.4.2 CREAMS 178
7.4.2.1 Filling, capping, and sealing machines to package creams 178
TABLE 80 CREAM PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 179
7.4.3 SUPPOSITORIES 179
7.4.3.1 Drying drug pipelines and growing costs to limit segment growth 179
TABLE 81 SUPPOSITORY PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 180
7.4.4 OTHER SEMI-SOLID PACKAGING EQUIPMENT 180
TABLE 82 OTHER SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 181
7.5 OTHER PRODUCT PACKAGING EQUIPMENT 181
TABLE 83 OTHER PRODUCT PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 182
8 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY REGION 183
8.1 INTRODUCTION 184
FIGURE 41 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 184
TABLE 84 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY REGION,
2020–2027 (USD MILLION) 185
8.2 EUROPE 185
FIGURE 42 EUROPE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET SNAPSHOT 186
TABLE 85 EUROPE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 187
TABLE 86 EUROPE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 187
TABLE 87 EUROPE: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 188
TABLE 88 EUROPE: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 188
TABLE 89 EUROPE: LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 90 EUROPE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 91 EUROPE: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 190
TABLE 92 EUROPE: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 190
TABLE 93 EUROPE: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 191
8.2.1 GERMANY 191
8.2.1.1 Germany to witness highest growth rate in European market 191
TABLE 94 GERMANY: KEY MACROINDICATORS 192
TABLE 95 GERMANY: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 192
TABLE 96 GERMANY: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 193
TABLE 97 GERMANY: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 193
TABLE 98 GERMANY: LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 194
TABLE 99 GERMANY: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 194
TABLE 100 GERMANY: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 195
TABLE 101 GERMANY: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 195
TABLE 102 GERMANY: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 196
8.2.2 ITALY 196
8.2.2.1 Growing consumption of OTC and generic drugs to drive market growth 196
TABLE 103 ITALY: KEY MACROINDICATORS 197
TABLE 104 ITALY: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 197
TABLE 105 ITALY: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 198
TABLE 106 ITALY: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 198
TABLE 107 ITALY: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 199
TABLE 108 ITALY: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 199
TABLE 109 ITALY: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 200
TABLE 110 ITALY: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 200
TABLE 111 ITALY: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 201
8.2.3 UK 201
8.2.3.1 Growth in generics market alongside rising demand for prescription and OTC drugs to drive market growth 201
TABLE 112 UK: KEY MACROINDICATORS 201
TABLE 113 UK: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 202
TABLE 114 UK: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 202
TABLE 115 UK: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 203
TABLE 116 UK: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 203
TABLE 117 UK: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 204
TABLE 118 UK: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 204
TABLE 119 UK: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 205
TABLE 120 UK: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 205
8.2.4 FRANCE 206
8.2.4.1 Presence of leading pharmaceutical companies to drive market growth 206
TABLE 121 FRANCE: KEY MACROINDICATORS 206
TABLE 122 FRANCE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 206
TABLE 123 FRANCE: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 207
TABLE 124 FRANCE: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 207
TABLE 125 FRANCE: LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 208
TABLE 126 FRANCE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 208
TABLE 127 FRANCE: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 209
TABLE 128 FRANCE: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 209
TABLE 129 FRANCE: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 210
8.2.5 SPAIN 210
8.2.5.1 Rising geriatric population and growing generics market to propel market growth 210
TABLE 130 SPAIN: KEY MACROINDICATORS 211
TABLE 131 SPAIN: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 211
TABLE 132 SPAIN: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 212
TABLE 133 SPAIN: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 212
TABLE 134 SPAIN: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 213
TABLE 135 SPAIN: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 213
TABLE 136 SPAIN: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 214
TABLE 137 SPAIN: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 214
TABLE 138 SPAIN: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 215
8.2.6 SWITZERLAND 215
8.2.6.1 Growing generics market to drive market growth 215
TABLE 139 SWITZERLAND: KEY MACROINDICATORS 216
TABLE 140 SWITZERLAND: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 216
TABLE 141 SWITZERLAND: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 217
TABLE 142 SWITZERLAND: SECONDARY PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 217
TABLE 143 SWITZERLAND: LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 218
TABLE 144 SWITZERLAND: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 218
TABLE 145 SWITZERLAND: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 219
TABLE 146 SWITZERLAND: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 219
TABLE 147 SWITZERLAND: SEMI-SOLID PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 220
8.2.7 REST OF EUROPE 220
TABLE 148 ROE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 221
TABLE 149 ROE: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 221
TABLE 150 ROE: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 222
TABLE 151 ROE: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 222
TABLE 152 ROE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 223
TABLE 153 ROE: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 223
TABLE 154 ROE: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 224
TABLE 155 ROE: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 224
8.3 ASIA PACIFIC 225
FIGURE 43 ASIA PACIFIC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET SNAPSHOT 226
TABLE 156 APAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 227
TABLE 157 APAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 227
TABLE 158 APAC: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 228
TABLE 159 APAC: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 228
TABLE 160 APAC: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 229
TABLE 161 APAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 229
TABLE 162 APAC: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 230
TABLE 163 APAC: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 230
TABLE 164 APAC: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 231
8.3.1 CHINA 231
8.3.1.1 Favorable government initiatives to propel market growth 231
TABLE 165 CHINA: KEY MACROINDICATORS 232
TABLE 166 CHINA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 232
TABLE 167 CHINA: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 233
TABLE 168 CHINA: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 233
TABLE 169 CHINA: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 234
TABLE 170 CHINA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 234
TABLE 171 CHINA: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 235
TABLE 172 CHINA: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 235
TABLE 173 CHINA: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 236
8.3.2 JAPAN 236
8.3.2.1 Rising geriatric population and growth in generics market to drive market growth 236
TABLE 174 JAPAN: KEY MACROINDICATORS 237
TABLE 175 JAPAN: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 237
TABLE 176 JAPAN: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 238
TABLE 177 JAPAN: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 238
TABLE 178 JAPAN: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 239
TABLE 179 JAPAN: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 239
TABLE 180 JAPAN: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 240
TABLE 181 JAPAN: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 240
TABLE 182 JAPAN: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 241
8.3.3 INDIA 241
8.3.3.1 Low manufacturing cost and skilled workforce to attract outsourcing and investments 241
TABLE 183 INDIA: KEY MACROINDICATORS 242
TABLE 184 INDIA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 242
TABLE 185 INDIA: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 243
TABLE 186 INDIA: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 243
TABLE 187 INDIA: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 244
TABLE 188 INDIA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 244
TABLE 189 INDIA: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 245
TABLE 190 INDIA: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 245
TABLE 191 INDIA: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 246
8.3.4 SOUTH KOREA 246
8.3.4.1 Rising healthcare spending and increasing government initiatives to propel clinical trials 246
TABLE 192 COUNTRIES BUYING THE MOST KOREAN DRUGS 247
TABLE 193 SOUTH KOREA: KEY MACROINDICATORS 247
TABLE 194 SOUTH KOREA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 247
TABLE 195 SOUTH KOREA: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 248
TABLE 196 SOUTH KOREA: SECONDARY PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 248
TABLE 197 SOUTH KOREA: LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 249
TABLE 198 SOUTH KOREA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 249
TABLE 199 SOUTH KOREA: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 250
TABLE 200 SOUTH KOREA: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 250
TABLE 201 SOUTH KOREA: SEMI-SOLID PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 251
8.3.5 REST OF APAC 251
TABLE 202 ROAPAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 252
TABLE 203 ROAPAC: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 252
TABLE 204 ROAPAC: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 253
TABLE 205 ROAPAC: LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 253
TABLE 206 ROAPAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 254
TABLE 207 ROAPAC: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 254
TABLE 208 ROAPAC: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 255
TABLE 209 ROAPAC: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 255

Contract Research Organization (CROs) Services Market by Type (Early phase, Clinical, Lab, Consulting), Therapeutic Area (Oncology, Infectious Disease...

Publisher:        MarketsandMarkets

# of Pages:        408

Rating: 

1 User License $4,950

Publication Date:  March, 2022

Price:       $4,950 / User License




1 INTRODUCTION 55
1.1 OBJECTIVES OF THE STUDY 55
1.2 MARKET DEFINITION 56
1.2.1 INCLUSIONS & EXCLUSIONS 56
1.3 MARKET SCOPE 57
FIGURE 1 CRO SERVICES MARKET 57
1.3.1 YEARS CONSIDERED FOR THE STUDY 58
1.4 CURRENCY 58
1.5 LIMITATIONS 58
1.6 STAKEHOLDERS 59
1.7 SUMMARY OF CHANGES 59
2 RESEARCH METHODOLOGY 61
2.1 RESEARCH DATA 61
FIGURE 2 RESEARCH DESIGN 61
2.1.1 SECONDARY DATA 62
2.1.2 PRIMARY DATA 62
FIGURE 3 CRO SERVICES MARKET: BREAKDOWN OF PRIMARIES 63
2.2 MARKET SIZE ESTIMATION 64
FIGURE 4 MARKET SIZE ESTIMATION—BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF CRO SERVICES IN THE MARKET 64
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021 64
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021 65
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 66
FIGURE 7 CRO SERVICES MARKET: CAGR PROJECTIONS, 2022–2027 67
FIGURE 8 CRO SERVICES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES 67
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 68
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 69
FIGURE 10 DATA TRIANGULATION METHODOLOGY 69
2.5 INSIGHTS FROM PRIMARIES 70
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS 70
2.6 RESEARCH ASSUMPTIONS 70
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS 71
2.7 RISK ANALYSIS 71
3 EXECUTIVE SUMMARY 72
FIGURE 12 CRO SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 72
FIGURE 13 CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2022 VS. 2027 (USD MILLION) 73
FIGURE 14 CRO SERVICES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 74
FIGURE 15 GEOGRAPHICAL SNAPSHOT: CRO SERVICES MARKET 75
4 PREMIUM INSIGHTS 76
4.1 CRO SERVICES MARKET OVERVIEW 76
FIGURE 16 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH 76
4.2 NORTH AMERICA: CRO SERVICES MARKET SHARE, BY SERVICE & COUNTRY (2021) 77
FIGURE 17 CLINICAL RESEARCH SERVICES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN CRO SERVICES MARKET IN 2021 77
4.3 CRO SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 78
FIGURE 18 CLINICAL RESEARCH SERVICES SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2027 78
4.4 CRO SERVICES MARKET SHARE, BY END USER, 2021 78
FIGURE 19 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2021 78
4.5 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 79
FIGURE 20 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH IN THE CRO SERVICES MARKET FROM 2022 TO 2027 79
5 MARKET OVERVIEW 80
5.1 INTRODUCTION 80
5.2 MARKET DYNAMICS 80
FIGURE 21 CRO SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 80
TABLE 1 CRO SERVICES MARKET: IMPACT ANALYSIS 81
5.2.1 DRIVERS 81
5.2.1.1 Increasing investment in pharmaceutical R&D 81
FIGURE 22 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026 82
FIGURE 23 ACTIVE PHARMACEUTICAL PIPELINE, 2011–2021 83
5.2.1.2 Increasing number of clinical trial 83
FIGURE 24 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2021) 83
5.2.1.3 High cost of in-house drug development 84
FIGURE 25 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION) 84
5.2.1.4 Rising prevalence of orphan and rare diseases 85
5.2.2 OPPORTUNITIES 85
5.2.2.1 Growth in the drugs and biologics market despite the COVID-19 pandemic 85
FIGURE 26 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY THE US FDA (2011–2021) 85
TABLE 2 LIST OF BIOLOGICS APPROVED BY THE US FDA (2021) 86
5.2.2.2 Rising demand for specialized testing services among end users 86
5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies 87
5.2.3 CHALLENGES 87
5.2.3.1 Shortage of skilled professionals for clinical trials 87
5.2.3.2 Requirement for unique analytical testing approaches for innovative formulations 88
5.2.4 MARKET TRENDS 88
5.2.4.1 Growing adoption of artificial intelligence-based tools for drug discovery 88
5.2.4.2 Increased outsourcing to emerging Asian economies 89
5.2.4.3 CRO industry consolidation 90
TABLE 3 LIST OF ACQUISITIONS 90
5.2.4.4 Integrated end-to-end R&D service solutions 91
5.3 RANGES/SCENARIOS 91
FIGURE 27 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE CRO SERVICES MARKET 91
5.4 IMPACT OF COVID-19 OUTBREAK ON THE CRO SERVICES MARKET 92
FIGURE 28 CRO SERVICES MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019–2021 92
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 94
FIGURE 29 REVENUE SHIFT & NEW POCKETS FOR CRO SERVICE PROVIDERS 94
5.6 PRICING ANALYSIS 94
TABLE 4 AVERAGE SELLING PRICE OF CRO SERVICES, BY REGION (2020) 95
5.7 VALUE CHAIN ANALYSIS 95
FIGURE 30 VALUE CHAIN ANALYSIS OF THE CRO SERVICES MARKET: CLINICAL RESEARCH PHASES ADD MAXIMUM VALUE 96
5.8 ECOSYSTEM ANALYSIS 97
FIGURE 31 ECOSYSTEM ANALYSIS: CRO SERVICES MARKET 97
TABLE 5 SUPPLY CHAIN ECOSYSTEM 98
5.9 TECHNOLOGY ANALYSIS 99
5.10 CASE STUDIES 100
5.10.1 COVANCE FSPX DATA ANALYSIS WAS USED TO DETERMINE THE ELIGIBILITY OF PATIENTS ENROLLED FOR ONCOLOGY CLINICAL TRIALS 100
5.10.2 IQVIA PROVIDES END-TO-END CLINICAL SUPPORT TO SPONSOR 100
5.11 KEY CONFERENCES & EVENTS IN 2022–2023 100
TABLE 6 CRO SERVICES MARKET: DETAILED LIST OF CONFERENCES & EVENTS 100
5.12 REGULATORY ANALYSIS 101
5.12.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
5.13 PORTER’S FIVE FORCES ANALYSIS 107
TABLE 11 CRO SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 107
5.13.1 THREAT OF NEW ENTRANTS 107
5.13.2 THREAT OF SUBSTITUTES 107
5.13.3 BARGAINING POWER OF BUYERS 108
5.13.4 BARGAINING POWER OF SUPPLIERS 108
5.13.5 DEGREE OF COMPETITION 108
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 109
5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 109
FIGURE 32 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS OF CRO SERVICES 109
5.14.2 BUYING CRITERIA FOR CRO SERVICES 109
FIGURE 33 KEY BUYING CRITERIA FOR END USERS 109
6 CRO SERVICES MARKET, BY TYPE 110
6.1 INTRODUCTION 111
TABLE 12 CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 111
6.2 CLINICAL RESEARCH SERVICES 111
TABLE 13 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES AS OF MARCH 2022, BY LOCATION 112
TABLE 14 EXAMPLES OF CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS 112
FIGURE 34 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2020 VS. 2021 113
TABLE 15 CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 114
TABLE 16 CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 114
TABLE 17 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 18 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 115
TABLE 19 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 115
TABLE 20 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 115
6.2.1 PHASE III CLINICAL RESEARCH SERVICES 116
6.2.1.1 Rising cost of Phase III trials and high number of patients recruited in these trials to drive the demand for cost-effective CRO services 116
TABLE 21 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE III STUDY 116
TABLE 22 PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 117
TABLE 23 NORTH AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 24 EUROPE: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 25 ASIA PACIFIC: PHASE III CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 118
TABLE 26 LATIN AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 118
6.2.2 PHASE II CLINICAL RESEARCH SERVICES 118
6.2.2.1 Long duration of Phase II studies provides growth opportunities for CROs 118
TABLE 27 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES 119
TABLE 28 PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 119
TABLE 29 NORTH AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 120
TABLE 30 EUROPE: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 120
TABLE 31 ASIA PACIFIC: PHASE II CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 120
TABLE 32 LATIN AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 121
6.2.3 PHASE I CLINICAL RESEARCH SERVICES 121
6.2.3.1 Robust pipeline of pharmaceutical companies driving the growth of this market segment 121
TABLE 33 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE I STUDIES 121
TABLE 34 PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 122
TABLE 35 NORTH AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 122
TABLE 36 EUROPE: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 37 ASIA PACIFIC: PHASE I CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 38 LATIN AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 123
6.2.4 PHASE IV CLINICAL RESEARCH SERVICES 124
6.2.4.1 Increasing number of CROs are providing post-marketing surveillance 124
TABLE 39 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES 124
TABLE 40 PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 125
TABLE 41 NORTH AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 125
TABLE 42 EUROPE: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 125
TABLE 43 ASIA PACIFIC: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 126
TABLE 44 LATIN AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 126
6.3 EARLY-PHASE DEVELOPMENT SERVICES 126
FIGURE 35 DRUGS IN PIPELINE, BY THERAPEUTIC AREA (2021) 127
TABLE 45 EXAMPLES OF EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY MARKET PLAYERS 127
TABLE 46 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 128
TABLE 47 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 128
TABLE 48 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129
TABLE 49 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129
TABLE 50 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129
TABLE 51 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 130
6.3.1 CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES 130
6.3.1.1 CMC services are widely used to check the quality standards of drugs 130
TABLE 52 CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 130
TABLE 53 NORTH AMERICA: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 131
TABLE 54 EUROPE: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 131
TABLE 55 ASIA PACIFIC: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 131
TABLE 56 LATIN AMERICA: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 132
6.3.2 PRECLINICAL SERVICES 132
TABLE 57 PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 58 PRECLINICAL SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 133
TABLE 59 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 133
TABLE 60 EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 133
TABLE 61 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 134
TABLE 62 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 134
6.3.2.1 Pharmacokinetics/pharmacodynamics services 134
6.3.2.1.1 Importance of studies to determine the pharmacokinetic behavior of drug candidates is increasing 134
TABLE 63 PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 135
TABLE 64 NORTH AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 135
TABLE 65 EUROPE: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136
TABLE 66 ASIA PACIFIC: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136
TABLE 67 LATIN AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136
6.3.2.2 Toxicology testing services 137
6.3.2.2.1 Demand for toxicology testing is increasing to prevent late-stage failures 137
TABLE 68 TOXICOLOGY TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 137
TABLE 69 NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 70 EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 138
TABLE 71 ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 72 LATIN AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 139
6.3.2.3 Other preclinical services 139
TABLE 73 OTHER PRECLINICAL SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 139
TABLE 74 NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 140
TABLE 75 EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 140
TABLE 76 ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 140
TABLE 77 LATIN AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 141
6.3.3 DISCOVERY STUDIES 141
6.3.3.1 Rising importance of CRO services for target identification and validation to promote segment growth 141
TABLE 78 DISCOVERY STUDIES MARKET, BY REGION, 2020–2027 (USD MILLION) 141
TABLE 79 NORTH AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 142
TABLE 80 EUROPE: DISCOVERY STUDIES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 142
TABLE 81 ASIA PACIFIC: DISCOVERY STUDIES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 142
TABLE 82 LATIN AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 143
6.4 LABORATORY SERVICES 143
TABLE 83 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS 143
TABLE 84 LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 144
TABLE 85 LABORATORY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 144
TABLE 86 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 144
TABLE 87 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 145
TABLE 88 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 145
TABLE 89 LATIN AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 145
6.4.1 ANALYTICAL TESTING SERVICES 146
TABLE 90 ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 146
TABLE 91 ANALYTICAL TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 146
TABLE 92 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 147
TABLE 93 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 147
TABLE 94 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 147
TABLE 95 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 148
6.4.1.1 Physical characterization services 148
6.4.1.1.1 Demand for physical characterization is increasing to reduce the risk of product failure 148
TABLE 96 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 148
TABLE 97 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 149
TABLE 98 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 149
TABLE 99 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 149
TABLE 100 LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 150
6.4.1.2 Raw material testing services 150
6.4.1.2.1 Demand for raw material testing services is increasing to ensure the quality and purity of raw materials 150
TABLE 101 RAW MATERIAL TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 150
TABLE 102 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 151
TABLE 103 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 151
TABLE 104 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 151
TABLE 105 LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 152
6.4.1.3 Batch release testing services 152
6.4.1.3.1 Comprehensive portfolio of batch release testing services offered by CROs to propel segment growth 152
TABLE 106 BATCH RELEASE TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 152
TABLE 107 NORTH AMERICA: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 153
TABLE 108 EUROPE: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 153
TABLE 109 ASIA PACIFIC: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 153
TABLE 110 LATIN AMERICA: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 154
6.4.1.4 Stability testing services 154
6.4.1.4.1 Stability testing is used to ensure the long-term quality, safety, and efficacy of pharmaceutical products 154
TABLE 111 STABILITY TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 155
TABLE 112 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 155
TABLE 113 EUROPE: STABILITY TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 155
TABLE 114 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 156
TABLE 115 LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 156
6.4.1.5 Other analytical testing services 156
TABLE 116 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 157
TABLE 117 NORTH AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 157
TABLE 118 EUROPE: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 157
TABLE 119 ASIA PACIFIC: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 158
TABLE 120 LATIN AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 158
6.4.2 BIOANALYTICAL TESTING SERVICES 158
6.4.2.1 Demand for bioanalytical testing has increased due to the growing use of macromolecules and biosimilars 158
TABLE 121 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 159
TABLE 122 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 159
TABLE 123 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 159
TABLE 124 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 160
TABLE 125 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 160
6.5 CONSULTING SERVICES 160
6.5.1 ADOPTION OF CONSULTING SERVICES IS INCREASING FOR QUALITY ASSURANCE PURPOSES 160
TABLE 126 CONSULTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 161
TABLE 127 NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 161
TABLE 128 EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 162
TABLE 129 ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 162
TABLE 130 LATIN AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 162
6.6 DATA MANAGEMENT SERVICES 163
6.6.1 DATA MANAGEMENT SERVICES EXPECTED TO RECORD THE HIGHEST CAGR DURING THE FORECAST PERIOD 163
TABLE 131 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS 163
TABLE 132 DATA MANAGEMENT SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 164
TABLE 133 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 164
TABLE 134 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 164
TABLE 135 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 165
TABLE 136 LATIN AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 165
7 CRO SERVICES MARKET, BY THERAPEUTIC AREA 166
7.1 INTRODUCTION 167
TABLE 137 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 167
7.2 ONCOLOGY 168
FIGURE 36 GLOBAL CANCER INCIDENCE, BY CANCER TYPE (2020) 168
FIGURE 37 NUMBER OF ONCOLOGY CLINICAL TRIALS STARTED GLOBALLY FROM
2011 TO 2021 (IN THOUSAND) 169
TABLE 138 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2021) 169
TABLE 139 CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2020–2027 (USD MILLION) 170
TABLE 140 CRO SERVICES MARKET FOR ONCOLOGY, BY REGION,
2020–2027 (USD MILLION) 170
TABLE 141 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 170
TABLE 142 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,
2020–2027 (USD MILLION) 171
TABLE 143 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 171
TABLE 144 LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 171
7.2.1 BREAST CANCER 172
7.2.1.1 Breast cancer is the most prevalent cancer 172
TABLE 145 CRO SERVICES MARKET FOR BREAST CANCER, BY REGION,
2020–2027 (USD MILLION) 172
TABLE 146 NORTH AMERICA: CRO SERVICES MARKET FOR BREAST CANCER,
BY COUNTRY, 2020–2027 (USD MILLION) 172
TABLE 147 EUROPE: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 173
TABLE 148 ASIA PACIFIC: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 173
TABLE 149 LATIN AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 173
7.2.2 LUNG CANCER 174
7.2.2.1 Drug approvals indicate increasing research against lung cancer 174
TABLE 150 CRO SERVICES MARKET FOR LUNG CANCER, BY REGION,
2020–2027 (USD MILLION) 174
TABLE 151 NORTH AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 174
TABLE 152 EUROPE: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY,
2020–2027 (USD MILLION) 175
TABLE 153 ASIA PACIFIC: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 175
TABLE 154 LATIN AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 175
7.2.3 COLORECTAL CANCER 176
7.2.3.1 Increasing number of clinical trials on treatments against colorectal cancer to drive segment growth 176
TABLE 155 CRO SERVICES MARKET FOR COLORECTAL CANCER, BY REGION,
2020–2027 (USD MILLION) 176
TABLE 156 NORTH AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 176
TABLE 157 EUROPE: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 177
TABLE 158 ASIA PACIFIC: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 177
TABLE 159 LATIN AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 177
7.2.4 PROSTATE CANCER 178
7.2.4.1 Increasing research initiatives on prostate cancer to drive segment growth 178
TABLE 160 CRO SERVICES MARKET FOR PROSTATE CANCER, BY REGION,
2020–2027 (USD MILLION) 178
TABLE 161 NORTH AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 178
TABLE 162 EUROPE: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 179
TABLE 163 ASIA PACIFIC: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 179
TABLE 164 LATIN AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 179
7.2.5 OTHER CANCERS 180
TABLE 165 CRO SERVICES MARKET FOR OTHER CANCERS, BY REGION,
2020–2027 (USD MILLION) 180
TABLE 166 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION) 180
TABLE 167 EUROPE: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION) 181
TABLE 168 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION) 181
TABLE 169 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION) 181
7.3 INFECTIOUS DISEASES 182
7.3.1 EPIDEMIC OUTBREAKS ARE NECESSITATING INCREASING DRUG DISCOVERY ACTIVITIES 182
TABLE 170 CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION,
2020–2027 (USD MILLION) 182
TABLE 171 NORTH AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 182
TABLE 172 EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 183
TABLE 173 ASIA PACIFIC: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 183
TABLE 174 LATIN AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 183
7.4 CARDIOVASCULAR SYSTEM DISORDERS 184
7.4.1 HIGH MORTALITY RATES DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS 184
TABLE 175 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2021) 184
TABLE 176 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2020–2027 (USD MILLION) 185
TABLE 177 NORTH AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 185
TABLE 178 EUROPE: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 185
TABLE 179 ASIA PACIFIC: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 186
TABLE 180 LATIN AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 186
7.5 NEUROLOGY 186
7.5.1 INCREASING INVESTMENT IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS TO DRIVE SEGMENT GROWTH 186
TABLE 181 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2021) 187
TABLE 182 CRO SERVICES MARKET FOR NEUROLOGY, BY REGION,
2020–2027 (USD MILLION) 188
TABLE 183 NORTH AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 188
TABLE 184 EUROPE: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,
2020–2027 (USD MILLION) 188
TABLE 185 ASIA PACIFIC: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 189
TABLE 186 LATIN AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 189
7.6 VACCINES 189
7.6.1 INCREASING INVESTMENTS IN VACCINE R&D TO DRIVE SEGMENT GROWTH 189
TABLE 187 CRO SERVICES MARKET FOR VACCINES, BY REGION,
2020–2027 (USD MILLION) 190
TABLE 188 NORTH AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION) 190
TABLE 189 EUROPE: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,
2020–2027 (USD MILLION) 190
TABLE 190 ASIA PACIFIC: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,
2020–2027 (USD MILLION) 191
TABLE 191 LATIN AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION) 191
7.7 METABOLIC DISORDERS/ENDOCRINOLOGY 191
7.7.1 INCREASING GLOBAL DIABETES POPULATION EXPECTED TO DRIVE SEGMENT GROWTH 191
FIGURE 38 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES,
2000–2045 (MILLION) 192
TABLE 192 CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2020–2027 (USD MILLION) 192
TABLE 193 NORTH AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 193
TABLE 194 EUROPE: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 193
TABLE 195 ASIA PACIFIC: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 193
TABLE 196 LATIN AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 194
7.8 IMMUNOLOGICAL DISORDERS 194
7.8.1 GROWING DRUGS PIPELINE FOR IMMUNOLOGICAL DISORDERS TO DRIVE SEGMENT GROWTH 194
TABLE 197 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2020–2027 (USD MILLION) 194
TABLE 198 NORTH AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 195
TABLE 199 EUROPE: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 195
TABLE 200 ASIA PACIFIC: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 195
TABLE 201 LATIN AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 196
7.9 PSYCHIATRY 196
7.9.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL SEGMENT GROWTH 196
TABLE 202 CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION,
2020–2027 (USD MILLION) 196
TABLE 203 NORTH AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2020–2027 (USD MILLION) 197
TABLE 204 EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,
2020–2027 (USD MILLION) 197
TABLE 205 ASIA PACIFIC: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2020–2027 (USD MILLION) 197
TABLE 206 LATIN AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2020–2027 (USD MILLION) 198
7.10 RESPIRATORY DISORDERS 198
7.10.1 INCREASING PREVALENCE OF RESPIRATORY DISORDERS TO SUPPORT SEGMENT GROWTH 198
TABLE 207 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2021) 198
TABLE 208 CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION,
2020–2027 (USD MILLION) 199
TABLE 209 NORTH AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 199
TABLE 210 EUROPE: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 200
TABLE 211 ASIA PACIFIC: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 200
TABLE 212 LATIN AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 200
7.11 DERMATOLOGY 201
7.11.1 INCREASING PREVALENCE OF SKIN DISORDERS TO PROPEL SEGMENT GROWTH 201
TABLE 213 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2021) 201
TABLE 214 CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION,
2020–2027 (USD MILLION) 202
TABLE 215 NORTH AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 202
TABLE 216 EUROPE: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY,
2020–2027 (USD MILLION) 202
TABLE 217 ASIA PACIFIC: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 203
TABLE 218 LATIN AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 203
7.12 OPHTHALMOLOGY 203
7.12.1 GROWING NEED FOR OPHTHALMOLOGY-RELATED CLINICAL TRIALS TO DRIVE SEGMENT GROWTH 203
TABLE 219 CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION,
2020–2027 (USD MILLION) 204
TABLE 220 NORTH AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 204
TABLE 221 EUROPE: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 204
TABLE 222 ASIA PACIFIC: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 205
TABLE 223 LATIN AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 205
7.13 GASTROINTESTINAL DISEASES 205
7.13.1 RISING INCIDENCE OF GASTROINTESTINAL DISEASES TO PROPEL SEGMENT GROWTH 205
TABLE 224 CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2020–2027 (USD MILLION) 206
TABLE 225 NORTH AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 206
TABLE 226 EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 206
TABLE 227 ASIA PACIFIC: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 207
TABLE 228 LATIN AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 207